Is Ozempic really worse than Big Tobacco? Breaking down the claims

What's this video probably claiming?

Based on the caption and the "worse than Big Tobacco" framing, this video almost certainly positions GLP-1 receptor agonists, specifically semaglutide marketed as Ozempic, as a dangerous drug being pushed on an unsuspecting public by a profit-hungry pharmaceutical industry. The seven-point list format suggests the creator is cycling through a fear-based catalog: nausea, vomiting, diarrhea as opening acts, then escalating to gastroparesis and intestinal blockage. The tobacco comparison is a rhetorical device designed to imply deliberate corporate concealment of known harms. Expect claims that side effects are underreported, that doctors are financially incentivized to prescribe, and possibly that weight regain after stopping proves the drug is addictive or creates dependency. These are real concerns worth examining. They are not, however, equivalent to a product designed to kill its users. The framing matters enormously here.

What does the science actually show?

The GI side effects are real and documented in the actual trial data. In the SUSTAIN and STEP trials, nausea occurred in roughly 44% of participants on semaglutide 2.4mg, vomiting in about 24%, and diarrhea in around 30%, compared to 16%, 6%, and 16% on placebo respectively (Wilding et al., 2021, NEJM). Most cases were mild to moderate and peaked during dose escalation. Gastroparesis is the more contested claim. A 2023 JAMA Internal Medicine study by Sodhi et al. found elevated risk of gastroparesis and bowel obstruction in GLP-1 users compared to bupropion-naltrexone users, with an adjusted hazard ratio of 3.67 for gastroparesis. That sounds alarming. But absolute event rates were low, the comparison group matters a lot, and causality has not been firmly established. The FDA has updated labels, which is appropriate. That is not the same as a cover-up.

Where does the social media noise diverge from clinical reality?

The Big Tobacco comparison collapses under basic scrutiny. Tobacco causes roughly 480,000 deaths per year in the US alone, with harm built into its mechanism of action. Semaglutide's mechanism, slowing gastric emptying and modulating appetite via GLP-1 receptor agonism, is also why some patients experience GI distress. The side effect profile is not hidden, it is in the prescribing information and was reported in every Phase 3 trial. The Sodhi et al. gastroparesis finding is worth taking seriously, but the study had significant methodological limitations including reliance on insurance claims data and potential confounding from obesity itself, a known gastroparesis risk factor. Weight regain after stopping is also real, documented at around 2/3 of lost weight returning within a year (Wilding et al., 2022, Diabetes, Obesity and Metabolism), but that reflects the chronic nature of obesity as a condition, not drug addiction by any pharmacological definition.

What should you actually know?

GLP-1 receptor agonists carry real risks that deserve honest disclosure. GI side effects affect a meaningful percentage of users and cause some people to discontinue. The gastroparesis signal warrants ongoing surveillance and the FDA label update was the right call. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not take semaglutide, full stop. Pancreatitis risk, while rare, is also on the label. These are not hidden facts. They are in the clinical literature and in every informed consent conversation that should happen before a prescription is written. What this video almost certainly does is take legitimate documented side effects, strip them of context, statistical rates, and comparison to treatment alternatives, and weaponize them to generate fear. Obesity is associated with cardiovascular disease, type 2 diabetes, sleep apnea, and significantly reduced life expectancy. Dismissing an evidence-backed treatment without context is not consumer protection. It is misinformation with a wellness aesthetic.